



Care Pathways, Lean Management, Process Mining

Walter Sermeus, RN, PhD
Professor in Healthcare Management
KU Leuven



Our care pathway experience

- Belgian-Dutch Clinical Pathway Network
 - Since 2000, more than 100 organizations, more than 1200 pathways developed
- European Pathway Association (www.e-p-a.org)
 - EQCP-study on COPD and Hip fracture (BE, IT, PT)
 - CP4ACS study on STEMI (BE)
 - Colorectal cancer surgery (BE, NL, FR, DE)
- ALS-Care (IE, BE, NL, IT, UK, DE)
 - Funded by JPND (2014-17)

Outline

- What are care pathways ?
- Why care pathways ?
- How are care pathways developed ?
 - Some general principles
- How are care pathways evaluated?
 - What is the available evidence ?
 - Evaluation of the evaluation

ON CARE PATHWAYS

We hear a lot about guidelines, which are supposed to ensure that the right patients gets the right treatment. This is a rather glib statement, but is underpinned by some interesting ideas, including:

- Clinical/Care pathway {
- ◆ **Diagnosis:** Treating the right patient
 - ◆ **Treatment:** Treating the right patient right
 - ◆ **Organisation:** Treating the right patient right at the right time
 - ◆ **Pathway:** Treating the right patient right at the right time and in the right way

Guidelines are supposed to cover this, but they mostly cover just the first two steps. There is more to delivering good care than that. It requires good organisation - what one might call management, except that many of us now see that word as meaning anything but organisation. And it requires that we perform actions in ways that are known to deliver good quality care.

Definition of a Care Pathway

- Care pathways are a **complex intervention** for the mutual decision making and organization of predictable care for a well-defined group of patients during a well defined period.
- Defining characteristics of care pathways include:
 - an explicit statement of the **goals and key elements** of care based on evidence, best practice, and patient expectations.
 - the facilitation of the communication, **coordination of roles, and sequencing** the activities of the multidisciplinary care team, patients and their relatives.
 - the documentation, monitoring, and **evaluation of variances and outcomes**; and
 - the **identification of the appropriate resources**.
- The aim of a care pathway is to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources.”

Care Pathway Template

Area responsible
for care—may be used for
tracking outcomes &
patient satisfaction

Patient:
DRG#:
Date Admit:
Date Path Begun:

Diagnosis:
Targeted LOS
Expected LOS:
Actual LOS:

	Date:	Discharge Outcomes							
Care Element	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	
Care Unit									
Consults									
Test/Labs	m u								
Treatments	m u								
Medications									
Assessments									
Symptom/Pain Control									
Activity/Safety									
Teaching									
Nutrition									
Discharge Planning									
Intermediate Patient Outcomes									
Variance Code/Comments—See Back of Pathway									

Trending & Variance
Summaries

"Milestones"



Example: care pathway for hip arthroplasty

Figuur

Admittir...
Surgery: _____
Consulting physicians: _____
Allergies: _____
History: _____
IV: _____
Procedure: _____
Room number: _____

	Pre-hospital	Post-op Amit	Post-op day 1	PO day 2	PO day 3	PO day 4	PO day 5	PO day 6	PO day 7
Consults	Medical clearance if necessary Evaluate need for SS consult		PT consult & therapy; BID Re-evaluate SS needs	PT BID Home Care Evaluation	PT BID	PT BID One visit by OT to assist with ADLs as indicated	PT BID	PT BID	
Tests	CXR, CBC, UA, PT, SMA20, EKG, Labs appropriate for age & health 72 hrs before	T & C2 units X-ray	H & H PT (if on coumadin)	H & H PT	H & H PT	PT	PT	PT	PT
Mobility	Bedrest; tip unaffected side 30° HOB pm	Hip exercises Chair BID Stand/amb...	Continue exercises Chair BID Amb BID	Continue mobility BRP with ETS	Continue mobility	Continue mobility	Continue mobility Stairs	Continue mobility	
Treatments	ABD pillow, trapeze Drain IV therapy, triflow q2° DVT prophylaxes: (TED, coumadin, ASA, thrombogards)	ABD pillow, Drain, Trapeze IV therapy, triflow q2° DVT prophylaxes:	ABD pillow, trapeze DC Drain DC IV DVT proph	ABD pillow, Triflow DVT proph	ABD pillow, Triflow DVT proph	ABD pillow, Triflow DVT proph	ABD pillow, Triflow DVT proph	ABD pillow, Triflow DVT proph	
Meds	Pain Med (PCA, IM) Antibiotics	DC Antibiotics	Evaluate PCA PO pain meds	PO pain meds pm					
Nutrition metabolic	DAT ...	DAT ...	DAT ...	DAT ...	DAT ...	DAT ...	DAT ...	DAT ...	DAT ...
Elimination	Catheter of choice prn st cath ... foley after 3rd time		DC foley Eval. bowel function (BOCO)	Maintain normal bowel pattern	Maintain normal bowel pattern	Maintain normal bowel pattern	Maintain normal bowel pattern	Maintain normal bowel pattern	
Health/home management	Tour ECF	High risk assessment Assess need for ECF		Complete transfer from identify Dr. to follow	Prescription for home equipment identified by PT To ECF (if approp.)		Order Equipment	Equipment delivered	
Health perception	THA pre-op teaching by Ortho. Clinician	Instruct on post-op teaching	Instruct on hip precautions	Discharge teaching if to ECF		Discharge teaching	Reinforce D/C teaching		
signature									

To ECF: Outcomes:	Date met:	If Home: Outcomes:	Date Met:
1. In-out of bed with assistance.		1. In-out of bed independently or with minimal assist.	
2. On-off commode or chair with assistance.		2. On-off commode or chair independently or with minimal assist.	
3. Ambulate 25 feet with assistive devices with assistance.		3. Ambulates 75 feet independently with assistive devices	
4. Temperature below 100° for 24 hours		4. Utilizes oral analgesics for pain control.	
5. Utilizes oral analgesics for pain control		5. Evidence of wound healing, no drainage.	
6. Evidence of wound healing, no drainage.		6. Demonstrates safe hip precautions by appropriately answering questions.	
7. Demonstrate safe hip precautions by appropriately answering questions		7. Re-establish elimination pattern.	
8. Voiding without difficulty and has moved bowels at least once.			

Date clinical path reviewed by MD _____

Admitting RN _____

Care pathways for patients

ADVANCING MEDICINE SINCE 1826



YALE NEW HAVEN
HEALTH

YALE-NEW HAVEN HOSPITAL



20 York Street, New Haven, CT 06510-3202
Main phone number: (203) 688-4242

NEED A DOCTOR?, use our
[online service](#), or call (888) 700-6543

Yale-New Haven Hospital, Advancing Medicine Since 1826,
20 York Street, New Haven, CT 06510-3202. Main phone
number: (203) 688-4242.


or [Continue...](#)

[Children's Hospital](#) | [Psychiatric Hospital](#) | [Directions & Parking](#) | [Employment at YNHH](#)


So should you be on a patient pathway?

If you are admitted for a high risk or complex procedure, you should ask if your hospital can provide you with a pathway. Be sure to ask your doctor or hospital if you will be on a pathway before you are admitted to the hospital. The pathway can answer many questions you may not know to ask. You will also be able to familiarize yourself with the likely schedule of care.

Stacey-diagram




Care pathway models for coordination






How do care
pathways work?

Business Process Orientation




MODEL HEALTH CARE ORGANISATION



Patient n°86: CEO Glenn Steele

- In the meantime, Geisinger continues to compile success stories, including that of CEO Steele, who became patient No. 86 in the ProvenCare CABG program. "I was in and out of the hospital in two-and-a-half days," he says. Casale, who was Steele's surgeon, says the case opened his eyes to how complex a routine operation really is: "Two weeks after, the head of our IT group called me and said, 'Al, I just looked through [Steele's] chart, and I want to send you a list of everybody that accessed the medical record from the time he was seen in the clinic to two weeks post-op.' There were 113 people listed -- and every one had an appropriate reason to be in that chart. It shocked all of us. We all knew this was a team sport, but to recognize it was that big a team, every one of whom is empowered to screw it up -- that makes me toss and turn in my sleep."



Active components of Care Pathways: how do they work?

EBM

Systematic
Implementation

Interdisciplinary
teamwork

Process Evaluation
Operations - Lean

Active components of Care Pathways: how do they work?

EBM

Systematic
Implementation

Interdisciplinary
teamwork

Process Evaluation
Operations - Lean

Effectiveness: Adherence to evidence-based guidelines



SPECIAL ARTICLE

The Quality of Health Care Delivered to Adults in the United States

Elizabeth A. McGlynn, Ph.D., Steven M. Asch, M.D., M.P.H., John Adams, Ph.D., Joan Keesey, B.A., Jennifer Hicks, M.P.H., Ph.D., Alison DeCristofaro, M.P.H., and Eve A. Kerr, M.D., M.P.H.

Table 5. Adherence to Quality Indicators, According to Condition.*

Condition	No. of Indicators	No. of Participants Eligible	Total No. of Times Indicator Eligibility Was Met	Percentage of Recommended Care Received (95% CI)	Information about the extent to which standard processes in every element of quality — are delivered in the United States.
Senile cataract	10	159	602	78.7 (73.3–84.2)	A sample of adults living in 12 metropolitan areas in the United States received written records for the most recent two-year period and used this information to construct aggregate scores.
Breast cancer	9	192	202	75.7 (69.9–81.4)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Prenatal care	39	134	2920	73.0 (69.5–76.6)	little difference among the proportion of recommended prenatal care (95 percent), the proportion of recommended acute care provided for chronic conditions (73.0 percent), and the proportion of recommended care provided for preventive care. We then constructed aggregate scores.
Low back pain	6	489	3391	68.5 (66.4–70.5)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Coronary artery disease	37	410	2083	68.0 (64.2–71.8)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Hypertension	27	1973	6643	64.7 (62.6–66.7)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Congestive heart failure	36	104	1438	63.9 (55.4–72.4)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Cerebrovascular disease	10	101	210	59.1 (49.7–68.4)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Chronic obstructive pulmonary disease	20	169	1340	58.0 (51.7–64.4)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.
Depression	14	770	3011	57.7 (55.2–60.2)	percent (95 percent confidence interval, 54.3 to 55.5) of recommended care.

RAND:
- 30 conditions
- 439 indicators
- 54.9%

N Engl J Med 2003;348:2635-45.
Copyright © 2003 Massachusetts Medical Society.

KU LEUVEN

An International Study of Adherence to Guidelines for Patients Hospitalised with a COPD Exacerbation


Deborah Seys, Luk Bruyneel, Marc Decramer, Cathy Lodewijckx,
Massimiliano Panella, Walter Sermeus, Paulo Boto & Kris Vanhaecht

To cite this article: Deborah Seys, Luk Bruyneel, Marc Decramer, Cathy Lodewijckx, Massimiliano Panella, Walter Sermeus, Paulo Boto & Kris Vanhaecht (2016): An International Study of Adherence to Guidelines for Patients Hospitalised with a COPD Exacerbation, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, DOI: [10.1080/15412555.2016.1257599](https://doi.org/10.1080/15412555.2016.1257599)

Table 2. Overview process indicators for the in-hospital management of a COPD exacerbation.

	Patients n/N (%)	Hospital Median (Q1–Q3)	Expert consensus rate (12)
Diagnostic management			
Performance of arterial blood gas (ABG) measurement during first 24 hours of admission	325/378 (86.0)	77.5% (55.3–88.7)	82.9
Performance of chest X-ray during first 24 hours of admission	232/378 (61.4)	80.0% (0.0–100.0)	68.6
Pharmacological management			
Prescription of antibiotics	231/378 (61.1)	76.0% (0.0–93.8)	88.6
Prescription of short-acting bronchodilators during hospitalisation	229/378 (60.6)	63.1% (17.5–95.0)	60.0
Prescription of long-acting bronchodilators during hospitalisation	166/378 (43.9)	21.3% (0.0–84.9)	88.6
Prescription of 30–40 mg of oral prednisolone daily for 7–10 days	19/378 (5.0)	0.0% (0.0–0.0)	85.7
Non-pharmacological management			
Administration of controlled oxygen therapy in patients hypoxemic during admission	81/84 (96.4)	100.0% (100.0–100.0)	100.0
Assessment of smoking status	332/378 (87.8)	93.1% (80.2–100.0)	91.4
Patient received influenza vaccination within the past year	230/378 (60.8)	64.3% (52.6–79.4)	68.6
ABG measurement 1 or 2 days prior to discharge in patients hypoxemic during a COPD exacerbation	54/93 (58.1)	60.0% (16.7–100.0)	82.9
Patient received pneumococci vaccination within the past five years	168/378 (44.4)	43.3% (29.6–67.6)	68.6
Prescription of home oxygen therapy in patients with hypoxemic at discharge	10/24 (41.7)	50.0% (0.0–100.0)	100.0
Nutritional assessment (BMI)	115/378 (30.4)	9.4% (0.0–73.2)	51.4
Referral to pulmonary revalidation during the past year	109/378 (28.8)	14.2% (9.2–49.0)	100.0
Nutritional management in patients with overweight	9/53 (17.0)	0.0% (0.0–12.5)	65.7
Adequate discharge management	42/378 (11.1)	0.0% (0.0–17.4)	80.0
Education regarding inhaler therapy in patients in which inhaler therapy is prescribed	36/339 (10.6)	0.0% (0.0–0.0)	94.3
Performance of revalidation tests during the past year (inclusive current hospitalisation)	23/378 (6.1)	0.0% (0.0–8.3)	94.3
Nutritional management in patients with underweight	4/88 (4.5)	0.0% (0.0–0.0)	60.0
Education regarding home oxygen therapy in patients in which home oxygen is prescribed	5/132 (3.8)	0.0% (0.0–0.0)	88.6
Smoking cessation intervention in active smokers at admission	2/78 (2.6)	0.0% (0.0–0.0)	91.4




Importance – Performance Analysis (IPA)



IPA OF A SELECTION OF CARE PATHWAYS



COPD

Seys et al,
2017






HIP#

Seys et al,
2017



STeMI

Aeyels et al,
2017



Active components of Care Pathways: how do they work?

EBM

Systematic
Implementation

Interdisciplinary
teamwork

Process Evaluation
Operations - Lean

GRPI-model of team effectiveness




FIGURE 2


The GRPI Model of Team Effectiveness—Rubin, Plovnick, and Fry Model (1977)

Rubin, Plovnick, and Fry Model—The GRPI Model of Team Effectiveness

This model by Rubin, Plovnick, and Fry (1977) is one of the oldest models of team effectiveness. It is sometimes referred to as the “GRPI Model,” which stands for Goals, Roles, Processes, and Interpersonal Relationships. The authors present their model in terms of a pyramid similar to Maslow’s Hierarchy of Needs Theory (1954). However, unlike Maslow’s theory, this model starts at the top of the pyramid.

According to the model, a team always should begin with a team-level goal. After the goal is defined, the roles and responsibilities will become clearer. As individuals work together (processes), they will see that goals and responsibilities often are not sufficiently clear. Consequently, team members will need to redefine them. That redefinition enables them to adjust and readjust team processes, such as decision making, conflict resolution, and work flow. When doing all that, they will be developing the interpersonal relationships needed to relate to other team members and the team leader. See Figure 2.

% conflicts attributed to each level



Source: Tang & Wenzlik, 2008

ORIGINAL ARTICLE

Better Interprofessional Teamwork, Higher Level of Organized Care, and Lower Risk of Burnout in Acute Health Care Teams Using Care Pathways

A Cluster Randomized Controlled Trial

*Svin Deneckere, RN, MSc, PhD (Cand),** *Martin Euwema, MSc, PhD,†*
*Cathy Lodewijckx, RN, MSc, PhD,** *Massimiliano Panella, MD, PhD,‡§*
Timothy Mutsvari, PhD,|| *Walter Sermeus, RN, MSc, PhD,*‡*
and Kris Vanhaecht, RN, MSc, PhD‡*

KU LEUVEN

TABLE 4. Results of the Multilevel Logistic Regression Model for Ordinal or Binary Outcomes at the Cluster Level: Odds Ratios Explaining the Differences Between the Intervention and Control Group on (1) Effect of the Randomization Group, and Thus, the Effect of the Care Pathway; and (2) Effect of the Patient Group for Which the Care Pathway was Developed (COPD or PFF), that is a Covariate in the Multilevel Model

Indicators	Intervention	Control	Odds Ratio Random- ization Group [†]	Confidence Interval	Odds Ratio Patient Group [‡]	Confidence Interval
Team input indicators						
Leadership structure:						
No team leader/1 team leader/ shared leadership	No team leader: 4/17 1 team leader: 3/17 Shared leadership: 10/17	No team leader: 7/13 1 team leader: 3/13 Shared leadership: 3/13	4.271	1.021 to 17.861*	0.747	0.183 to 3.045
Coordinating mechanism (yes/no)						
Use of guidelines	Yes: 14/17	Yes: 5/13	7.683	1.387 to 42.548*	0.453	0.082 to 2.497
Use of interdisciplinary IT-system	Yes: 8/17	Yes: 8/13	0.562	0.122 to 2.589	3.195	0.687 to 14.87
Presence of a case manager	Yes: 6/17	Yes: 5/13	0.878	0.196 to 3.930	1.139	0.254 to 5.095
Team-training initiatives	Yes: 10/17	Yes: 4/13	3.218	0.700 to 14.791	1.022	0.226 to 4.624
Team process indicators						
Frequency of team meetings:						
Never: 0/17	Never: 3/13	5.834	1.325 to 25.684*	1.089	0.284 to 4.168	
Almost never: 2/17	Almost never: 4/13					
Every month: 2/17	Every month: 1/13					
Every 2 wk: 0/17	Every 2 wk: 1/13					
Weekly: 13/17	Weekly: 3/13					
Daily: 0/17	Daily: 1/13					

* $P < 0.05$.

[†]The odds ratios, with its confidence interval, present the difference between the intervention and control group in: (a) for binary outcomes: the chance that the indicator is present or not; and (b) for ordinal outcomes: the chance of being in a higher category for this indicator.

[‡]The odds ratios, with its confidence interval, present the difference between both patient groups for each indicator.

COPD indicates chronic obstructive pulmonary disease; PPF, proximal femur fracture.

Active components of Care Pathways: how do they work?

EBM

Systematic
Implementation

Interdisciplinary
teamwork

Process Evaluation
Operations - Lean

ARTICLE

The 7-phase method to design, implement and evaluate care pathways

Kris Vanhaecht RN MSc PhD^a, Eva Van Gerven MSc^b, Svin Deneckere RN MSc^c, Cathy Lodewijckx RN MSc^d, Ingrid Janssen MSc^e, Ruben van Zelm RN MSc^f, Paulo Boto MSc PhD^g, Rita Mendes MSc^h, Massimiliano Panella MD MPH PhDⁱ, Eva Biringer MD PhD^j and Walter Sermeus RN MSc PhD^k

Figure 1 The 7-Phase method





Figure 1 The 7-Phase method



Exploratory pathway analysis

Functional analysis	Process analysis	Organizational analysis	Case data analysis
<ul style="list-style-type: none"> • Existence/absence of activities • Activity co-existence • Additional analyses 	<ul style="list-style-type: none"> • Clinical pathway discovery • Process variant analysis • Recurring patterns • Additional analyses 	<ul style="list-style-type: none"> • Social network analysis (teams, hand-overs, interactions) • Task allocation • Additional analyses 	<ul style="list-style-type: none"> • Data-driven conditions • Correlations data and pathway structure • Additional analyses

Advanced pathway analysis

Efficiency analysis	Quality and conformance analysis
<ul style="list-style-type: none"> • Bottleneck analysis • Performance analysis and comparison of variants • Number and duration of diagnosis and treatment cycles • Additional analyses 	<ul style="list-style-type: none"> • Rule-based pathway analysis • Conformance analysis • Analysis of adverse events • Root-cause analysis for variation • Additional analyses

Examples of data analysis

Computers in Biology and Medicine 44 (2014) 88–99



Contents lists available at ScienceDirect

Computers in Biology and Medicine

journal homepage: www.elsevier.com/locate/cbm




Monitoring care processes in the gynecologic oncology department

Filip Caron ^{a,*}, Jan Vanthienen ^a, Kris Vanhaecht ^{b,c,d}, Erik Van Limbergen ^e,
Jochen De Weerdt ^{a,f}, Bart Baesens ^{a,g,h}




Analysis sub type	Analysis	Techniques/tools	Description
Exploratory analysis	Functional analysis	Activity existence in a clinical pathway	Heuristics miner [13] and LTL-checker [14]
	Process analysis	Clinical pathway discovery	Heuristics miner [13]
		Clinical pathway variant analysis	Heuristics miner [13]
		Recurring patterns in individual patient care	Trace alignment [15]
	Organizational analysis	Standard interaction and coordination between medical experts	Performance sequence diagram [16,17], Social network miner [18]
Advanced analysis	Case data analysis	Correlation between the activity log data and the activity sequence for individual patients	Custom-made rule patterns and process exploration
	Efficiency analysis	<i>Timestamps were to imprecise for efficiency analyses</i>	Correlation between (1) the presence of hyperthermia and the diagnosis codes, (2) the administration of paclitaxel and the diagnosis codes, (3) the administration of paclitaxel for ovarian cancer
	Quality and Conformance analysis	Rule-based pathway analysis	LTL-checker [14]
		Analysis of exceptional events	Custom-made rule patterns and process exploration

Examples



Social network analysis



Heuristic Miner

Examples

International Journal for Quality in Health Care 2011; Volume 23, Number 1: pp. 83–93
Advance Access Publication: 30 November 2010

(0.1093/ijqhc/maz071)

Exploring the relation between process design and efficiency in high-volume cataract pathways from a lean thinking perspective

ELLEN J. VAN VLIET¹, EELCO BREDENHOFF², WALTER SERMEUS¹, LUCAS M. KOP²,
JOHANNES C.A. SOL³ AND WIM H. VAN HARTEN²

	Lean framework	Hospital 1 (<i>n</i> = 9195)	Hospital 2 (<i>n</i> = 8761)	Hospital 3 (<i>n</i> = 4093)
Lead time in days	1	109.2	15.0	91.0
Access time	0	31.5	0.0	25.0
Waiting time for surgery	0	77.7	15.0	66.0
Number of hospital visits per patient	1.0	3.0	3.6	3.2
Patients with 1 hospital visit	100%	0 (0%)	0 (0%)	0 (0%)
Patients with 2 hospital visits	0%	4376 (48%)	0 (0%)	1274 (31%)
Index number direct costs per patient ^a	100.0	128.6	153.0	139.7

The outcomes in the lean framework column represent the ideal scores as achieved in Fig. 1.

^aThe direct costs per patient in the lean framework equalled an index value of 100.

KU LEUVEN

Active components of Care Pathways: how do they work?

EBM


Systematic
Implementation

Interdisciplinary
teamwork

Process Evaluation
Operations - Lean

Efficacy and efficiency of a lean cataract pathway: a comparative study

Ellen Joan van Vliet,^{1,2} Walter Sermeus,¹ Claudia M van Gaalen,² Johannes C A Sol,²
Jan M H Vissers³



Process flow of cataract pathway

Key interventions:

1. One-stop pre-assessment
2. Formulating surgical care plan based on patient record only
3. Next day telephone review by nurse
4. Final review 4 weeks after surgery by optometrist
5. Note: protocol exceptions for 2,3 and 4 so that patient is seen by eye surgeon




Table 1 Efficacy and efficiency of the lean cataract pathway

	Traditional pathway n= 591	Lean pathway n= 616	p Value†	p Value‡‡
Efficacy				
A. One-stop preassessments			<0.001‡	<0.001§
Actual care delivery*	188 (31.8%)	362 (58.8%)		
Expected care delivery*	NA	616 (100.0%)		
B. Formulating surgical care plan using the patient record only			<0.001‡	<0.001§
Actual care delivery*	72 (12.2%)	418 (67.9%)		
Expected care delivery*	NA	558 (90.6%)		
C. Next-day telephone review			<0.001‡	<0.001§
Actual care delivery*	0 (0%)	367 (59.5%)		
Expected care delivery*	NA	502 (81.5%)		
D. Final review by an optometrist			<0.001‡	<0.001§
Actual care delivery*	0 (0%)	257 (41.7%)		
Expected care delivery*	NA	517 (83.9%)		
Efficiency				
1. No of hospital visits per patient			<0.001¶	<0.001**
Actual care delivery†	5.7 (1.1)	4.4 (1.3)		
Expected care delivery†	NA	3.4 (0.6)		
2. Amount of ophthalmologist's time spent per patient in minutes			<0.001¶	<0.001**
Actual care delivery†	48.2 (2.2)	35.3 (6.7)		
Expected care delivery†	NA	28.6 (6.7)		
3. No of patients treated, related to ophthalmologist's time needed to treat one patient in traditional pathway			<0.001¶	<0.001**
Actual care delivery†	1.00 (0.0)	1.42 (0.3)		
Expected care delivery†	NA	1.76 (0.3)		

Actual care delivery in the lean pathway (2007) is compared with (1) actual care delivery in the traditional pathway (2004) and with (2) expected care delivery in the lean pathway, that is, care according to decision rules and service specifications, as stated in the lean pathway design.

*Number and percentage; †Mean with SD; ‡ χ^2 ; §McNemar; ¶Independent-samples t test; **Paired-samples t test; ††p Value of statistical testing between actual care delivery in the traditional pathway and actual care delivery in the lean pathway; ‡‡p Value of statistical testing between actual care delivery and expected care delivery in the lean pathway; NA, not applicable.

Effect on patient experiences

Table 2 Patients' experiences with quality of care in a cataract pathway with postoperative contact with ophthalmologists (control group with first-day review and final review conducted by ophthalmologists, ie, traditional care pathway) and a cataract pathway without postoperative contact with ophthalmologists (experimental group with telephone first-day review by a nurse and final review by an optometrist, ie, co-managed care pathway)

Q#	Control group (n=194)	Experimental group (n=289)	p Value	Multiple linear regression analysis**		Multiple logistic regression analysis**	
				B (SE)	p Value	OR (95% CI)	p Value
Patient experience with ophthalmologists							
Communication with ophthalmologist*	Q1–8	3.7 (0.4)	3.8 (0.4)	0.33§	0.01 (0.04)	0.75	NA
Global rating—ophthalmologist†	Q9	9.1 (1.3)	8.9 (1.3)	0.07§	-0.15 (0.12)	0.22	NA
Yes, enough contact with ophthalmologist‡	Q10	187 (96.4%)	267 (92.4%)	0.08¶	NA	0.51 (0.21 to 1.27)	0.15
Patient experience with overall care							
Global rating—hospital†	Q11	9.1 (1.3)	9.0 (1.0)	0.32§	-0.01 (0.11)	0.95	NA
Willingness-to-recommend*	Q12	3.9 (0.3)	3.9 (0.4)	0.14§	-0.05 (0.04)	0.21	NA
Patient experience with patient education							
Yes, emergency information provided‡	Q13	163 (84.0%)	254 (87.9%)	0.21¶	NA	1.20 (0.69 to 2.10)	0.53
Yes, postoperative instructions provided‡	Q14	119 (61.3%)	213 (73.7%)	<0.01¶	NA	1.78 (1.18 to 2.69)	<0.01

*Mean (SD) based on a Likert-scale response scores ranging from 1 (never/definitely not) to 4 (always/definitely).

†Mean (SD) based on a scale ranging from 0 (worst possible care) to 10 (best possible care).

‡Number and percentage of "yes" responses.

§Mann-Whitney test.

¶ χ^2 test.

**Statistical testing of the experimental group to the control group (reference group=control group), adjusted for age, health, sex, education, logMAR equivalent of postoperative corrected distance visual acuity, number of increased visual acuity lines and difference between intended and achieved refractive error in diopters.


Q#, number of the question in questionnaire (see figure 2); B (SE), β coefficient (SE).

Results of care pathways




Evaluation of Care Pathways

Care Pathway Compass



Results literature review 2000-2002

613 publications
Evaluation in 208/613 (34%)



	Positive effect	=	Negative effect
Clinical outcomes	65,6%	32%	2,4%
Service	62,2%	29,7%	8,1%
Process	86%	6,9%	6,9%
Team	83,3%	6,3%	10,4%
Financial	82,5%	13,5%	4%



This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

Effects of clinical pathways in the joint replacement: a meta-analysis


BMC Medicine 2009, **7**:32 doi:10.1186/1741-7015-7-32

A Barbieri (antonietta.barbieri@med.unipmn.it)
K Vanhaecht (kris.vanhaecht@med.kuleuven.be)
P Van Herck (pieter.vanherck@med.kuleuven.be)
W Sermeus (walter.sermeus@med.kuleuven.be)
F Faggiano (fabrizio.faggiano@med.unipmn.it)
S Marchisio (sara.marchisio@med.unipmn.it)
M Panella (panella@med.unipmn.it)

Review: Clinical pathway and total hip and knee arthroplasty

Comparison: 02 Care Pathway vs standard care

Outcome: 01 Postoperative complications



Review: Clinical pathway and total hip and knee arthroplasty
 Comparison: 01 Care Pathway vs standard care
 Outcome: 03 Length of hospital stay




Figure 6

Results Cochrane Systematic Review 2010

Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs (Review)

Rotter T, Kinsman L, James E, Machotta A, Gothe H, Willis J, Snow P, Kugler J



THE COCHRANE
COLLABORATION®

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library*
2010, Issue 3

<http://www.thecochranelibrary.com>



Clinical pathways effects on professional practice, patient outcomes, length of stay and hospital costs (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PLAIN LANGUAGE SUMMARY

Clinical pathways in hospitals.

Decision-making in hospitals has evolved from being opinion-based to being based on sound scientific evidence. This decision-making is recognised as evidence-based practice. Perpetual publication of new evidence combined with the demands of every-day practice makes it difficult for health professionals to keep up to date. Clinical pathways are document-based tools that provide a link between the best available evidence and clinical practice. They provide recommendations, processes and time-frames for the management of specific medical conditions or interventions. Clinical pathways have been implemented worldwide but the evidence about their impact from single trials is contradictory. This review aimed to summarise the evidence and assess the effect of clinical pathways on professional practice (e.g. quality of documentation), patient outcomes (e.g. mortality, complications), length of hospital stay and hospital costs.

Twenty-seven studies involving 11,398 participants were included for analysis. The main results were a reduction in in-hospital complications and improved documentation associated with clinical pathways. Complications assessed included wound infections, bleeding and pneumonia. Most studies reported a decreased length of stay and reduction in hospital costs when clinical pathways were implemented. Considerable variation in study design and settings prevented statistical pooling of results for length of stay and hospital costs. Generally poor reporting prevented the identification of characteristics common to successful clinical pathways.

The authors concluded that clinical pathways are associated with reduced in-hospital complications


- Lower LOS
- Less costs
- Better documentation
- Less complications

KU LEUVEN

General results



- Improved coördination (*Gittel, 2000*)
- Less variation (*Cannon, 2002; Panella, 2003*)
- Improved teamwork (*Deneckere, 2013*)
- Lower risk on burnout (*Seys 2017*)
- Decreased mortality (*Panella, 2009;*)
- Lower Length of Stay (*Barbieri, 2009*)
- Lower complications (*Rotter, 2010*)
- Lower cost (*Panella, 2003; Barbieri, 2009*)
- Higher patient satisfaction (*Renholm, 2002*)
- Lower readmission rate (*Vanhaecht, 2017*)



- Methods unclear
- Design
- Descriptive
- Content of the pathway
- Change mechanisms
- Sample size
- Indicators
- Sustainability
- ...

Evaluation of the evaluation

- Often no evaluation (2/3 of projects)
- Poor designs (mainly pre-post designs, case studies)
- Care pathway is not always fully described (nor control) – (what are you evaluating?)
- Small sample sizes – low power
- Systematic reviews: often negative because of large variability in interventions (- what are you combining)
- Context seems to highly important (support by management, ownership by teams, health system)

Conclusions

ON CARE PATHWAYS

We hear a lot about guidelines, which are supposed to ensure that the right patients gets the right treatment. This is a rather glib statement, but is underpinned by some interesting ideas, including:

- ◆ **Diagnosis:** Treating the right patient
- ◆ **Treatment:** Treating the right patient right
- ◆ **Organisation:** Treating the right patient right at the right time
- ◆ **Pathway:** Treating the right patient right at the right time and in the right way

Guidelines are supposed to cover this, but they mostly cover just the first two steps. There is more to delivering good care than that. It requires good organisation - what one might call management, except that many of us now see that word as meaning anything but organisation. And it requires that we perform actions in ways that are known to deliver good quality care.

Pulling it all together

Care pathways do not start from nowhere and nothing. It is not as if what we do usually is badly awry, and our experience in modern healthcare systems is the opposite. These large, complex, organisations looking at millions of individual people do a simply marvellous job for most people most of the time.

While recognising that, none of us could or would claim that everything is perfect. There is always room for improvement as our technology, experience, and support services improve. The issue is often not one of no change, but often one of too much change, but of the wrong sort.

In industry, care pathways would be called something else. A mix, perhaps, of good practice and quality control, plus a large helping of ongoing quality improvement. After all, care pathways involve not one action, but many, often in a complex package of care. In these complex packages, it is the combining of individual interventions in a management framework suited to local needs and abilities that is the critical factor.



THANK YOU FOR YOUR
ATTENTION